Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Income from Continuing Operations (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Income from Continuing Operations readings, the most recent being 634000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 115.7% to 634000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 489000.0, a 90.14% increase, with the full-year FY2025 number at 2339000.0, up 45.82% from a year prior.
  • Income from Continuing Operations hit 634000.0 in Q4 2025 for Arcadia Biosciences, up from 1152000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5592000.0 in Q4 2021 to a low of 5423000.0 in Q2 2021.
  • Median Income from Continuing Operations over the past 5 years was 1385000.0 (2024), compared with a mean of 1457750.0.
  • Biggest five-year swings in Income from Continuing Operations: surged 183.09% in 2023 and later crashed 793.14% in 2024.
  • Arcadia Biosciences' Income from Continuing Operations stood at 5592000.0 in 2021, then tumbled by 156.87% to 3180000.0 in 2022, then skyrocketed by 85.79% to 452000.0 in 2023, then crashed by 793.14% to 4037000.0 in 2024, then skyrocketed by 115.7% to 634000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 634000.0 (Q4 2025), 1152000.0 (Q3 2025), and 501000.0 (Q2 2025) per Business Quant data.